RNS & Investor News

2019

14 October OPTIBIOTIX HEALTH PLC (OPTI-GB): LP-LDL achieves two major milestones
goetzpartners securities Research
Disclaimer
Please note that this Equity Research publication is for Institutional Investor / Professional Investor use only and is not intended for Retail / Private client use. Any opinions, estimates or forecasts regarding OptiBiotix Health Plc's performance made by goetzpartners securities Limited analysts are theirs alone and do not represent opinions, forecasts or predictions of OptiBiotix Health Plc or its management.
09 October LPLDL® Pharmaceutical GMP process validation
18 September GoFigure® distribution agreement for Southern Africa
10 September OPTIBIOTIX (OPTI-GB): Microbiome-targeting, evidence-based food ingredients
goetzpartners securities Research
Disclaimer
Please note that this Equity Research publication is for Institutional Investor / Professional Investor use only and is not intended for Retail / Private client use. Any opinions, estimates or forecasts regarding OptiBiotix Health Plc's performance made by goetzpartners securities Limited analysts are theirs alone and do not represent opinions, forecasts or predictions of OptiBiotix Health Plc or its management.
28 August Director's Dealing
28 August Holding(s) in Company
28 August Directorate Change
28 August Half Year Report
12 August Manufacturing, supply and profit sharing agreement with Maxum Foods Pty Ltd.
29 July Transfer of certain SkinBioTherapeutics plc shares
18 July Online distribution agreement for SlimBiome® Medical
11 July Scientific and commercial update
03 July License agreement for LPLDL® in Japan
01 July LPLDL® license agreement with Kappa Bioscience AS for vascular health product
25 June Appointment of goetzpartners securities Limited
24 June Manufacturing, supply and profit sharing agreement with Agropur MSI, LLC
11 June Result of AGM
10 June License agreement for CholBiome® and CholBiome®x3 in Vietnam
29 May Director's dealing
28 May Appointment of CEO for ProBiotix Health Ltd
22 May GoFigure® distribution agreement for Poland
20 May LPLDL® license agreement for new application in hypertension
17 May Notice of AGM
14 May Distribution Agreement for SlimBiome® in Thailand
07 May License agreement for LPLDL® in personalised nutrition applications
02 May Investor evening
01 May OptiBiotix to launch SlimBiome® Medical to the EU market at Vitafoods Europe 2019
29 April Final Results
24 April SlimBiome® Medical launches in UK market
11 April SlimBiome® receives approval from FSSAI in India
09 April SlimBiome® Medical agreement for Bulgaria
27 March Grant of Options
27 March SweetBiotix®: Scientific and commercial update
20 March Exclusive distribution agreement for SlimBiome®
15 March Extension of term and territories for LPLDL® capsules with HLH Biopharma GmbH
13 March Exercise of Warrants and Issue of Equity
21 February LPLDL® determined GRAS by an Expert Panel in the United States
20 February Presentations at ProBiota - 2019
13 February Year-end Update
11 February OptiBiotix Health aiming to be big in Japan with latest deal
proactiveinvestors (website)
11 February Distribution agreement for Lactobacillus plantarum LPLDL® in Japan
07 February Supply agreement for LPLDL® in the Baltic States
18 January Exercise of Warrants and Issue of Equity
11 January Director Appointment
09 January Distribution agreement for cholesterol reducing CholBiome®
07 January OptiBiotix's SlimBiome gathers steam as subsidiary eyes potential IPO
proactiveinvestors (website)
07 January Manufacturing, supply and profit sharing agreement for SlimBiome®